NCT02152631 2026-02-06JUNIPEREli Lilly and CompanyPhase 3 Active not recruiting453 enrolled 18 charts
NCT02411448 2026-01-16RELAYEli Lilly and CompanyPhase 3 Active not recruiting545 enrolled 24 charts 2 FDA
NCT00977470 2025-10-15Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) MutationsMassachusetts General HospitalPhase 2 Active not recruiting76 enrolled 12 charts